NYS Entity Status
NYS Filing Date
JANUARY 02, 2013
NYS DOS ID#
475 ST. MARKS AVE
BROOKLYN, NEW YORK, 11238
NYS Entity Type
DOMESTIC NOT-FOR-PROFIT CORPORATION
2013 - MEDICINE FOR THE WORLD INC.
AROUND THE WEB
- 19th-Century Diary Suggests Slaves Are Buried in Brooklyn Lot
By MICHAEL WILSON - Friday Aug 4, 2017
- Neighborhood Joint: Staubitz Market in Brooklyn: 100 Years of Sawdust, Steaks and Chops
By ANDREW COTTO - Wednesday Jun 14, 2017
- Federal Jail in Brooklyn Faces a String of Sexual Assault Cases
By JOSEPH GOLDSTEIN - Tuesday Aug 1, 2017
- New York Today: New York Today: New Subway Clocks
By JONATHAN WOLFE - Monday Aug 7, 2017
Monday: Rolling out new subway clocks, the Corkscrew Theater Festival, and National Lighthouse Day.
- Critic's Notebook: Fringe Festival? Not This Summer. Fringe Spirit? Definitely.
By LAURA COLLINS-HUGHES - Tuesday Sep 5, 2017
A plantation-set adaptation of “The Cherry Orchard” and a scatological monologue are visceral reminders of theater’s power to unsettle.
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.